dihexa injectable Peptide Dihexa | Rize Up Medical

The most significant data comes from the REDEFINE trials, evaluating the co-administration of Cagrilintide and Semaglutide These findings highlight the synergistic potential of combining the amylin pathway (Cagrilintide) and the GLP-1 pathway (Semaglutide) to achieve superior metabolic and weight loss outcomes compared to either agent alone

Background materials : FDA says it intends to post background material and the live webcast link no later than two business days before the meeting

Updated June 2026 Medically reviewed 12 min read Important: This guide is for information only and does not replace medical advice

These reductions were accompanied by significant body weight loss, confirming a robust pharmacodynamic response